FDA rejects accelerated approval for Eli Lilly’s Alzheimer’s drug, donanemab
January 20, 2023Research and Development
Eli Lilly has announced that its accelerated approval bid for Alzheimer’s disease drug, donanemab, has been rejected by the FDA. …
Merck attempts to reduce levels of carcinogenic compounds in diabetes drugs
January 20, 2023Medical Communications
Pharmaceutical company Merck has announced that it is attempting to reduce levels of a cancer-causing compound which has been found …
Intas Pharmaceuticals under FDA scrutiny after oversight in GMP documents
January 20, 2023Manufacturing and Production
India-based manufacturer Intas Pharmaceuticals has been issued a Form 483 by the FDA after three investigators found a “cascade of …
Alnylam and PTC Therapeutics’ rare disease drugs given backing by NICE
January 20, 2023Medical Communications
Alnylam’s Amvuttra and PTC Therapeutics’ Translarna will be available to patients through the NHS after being backed by NICE, despite …
Genentech announce positive results from phase 3 IMbrave050 study
January 19, 2023Research and Development
Genentech, based in California, US, has announced positive results from its phase 3 IMbrave050 trial, after the study met its …
Abbott secures FDA approval for Navitor TAVI device
January 19, 2023Medical Communications
US-based medical device firm Abbott has secured FDA approval for Navitor to treat people with aortic stenosis who are at …
Moderna’s mRNA vaccine appears promising for older adults with RSV
January 19, 2023Research and Development
Moderna’s respiratory syncytial virus (RSV) vaccine has demonstrated positive levels of efficacy in older adults throughout a phase 3 trial. …
Johnson & Johnson cuts trial for its HIV vaccine following disappointing data
January 19, 2023Medical Communications
Johnson & Johnson (J&J) has announced that it has ended its clinical trial for its experimental HIV vaccine, following disappointing …
NICE recommends AMVUTTRA®▼ (vutrisiran) as treatment for a hereditary form of amyloidosis in draft guidance
January 19, 2023Business Services
MAIDENHEAD, UK, 19th January 2023 – Alnylam UK Limited, the leading RNA interference (RNAi) therapeutics company, today welcomed a draft …
Servier and Taiho Oncology Present Overall Survival Data for Trifluridine/Tipiracil (LONSURF®) In Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer at 2023 ASCO Gastrointestinal Cancers Symposium
January 19, 2023Business Services
PARIS, France, and PRINCETON, N.J., January 19, 2023 – Servier and Taiho Oncology, Inc., today announced the release of data …
NeoPhore completes extension to Series B financing to further advance discovery pipeline
January 19, 2023Business Services
Cambridge, UK, 19 January 2023 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the completion of its £21.5m …
AI tool to improve blood sugar management in type 1 diabetes patients
January 18, 2023Medical Communications
A new app, designed by researchers at Oregon Health & Science University (OSHU), uses artificial intelligence (AI) to assess blood …
Neuronetics Inc. announces efficacy of treatment for neurohealth disorders
January 18, 2023Research and Development
US-based commercial-stage medical technology company Neuronetics Inc., which focuses on designing, developing and marketing products that improve the quality of …
Shockwave Medical acquires Neovasc for $100m
January 18, 2023Research and Development
US-based cardiovascular medical device company Shockwave Medical has signed a deal to acquire specialty medical device company Neovasc for around …
Cambridge’s Experimental Cancer Medicine Centre to receive funding for clinical trials
January 18, 2023Medical Communications
The Experimental Cancer Medicine Centre (ECMC) in Cambridge is one of a selection of organisations to receive a share of …
PFIZER EXPANDS ‘AN ACCORD FOR A HEALTHIER WORLD’ PRODUCT OFFERING TO INCLUDE FULL PORTFOLIO FOR GREATER BENEFIT TO 1.2 BILLION PEOPLE IN 45 LOWER-INCOME COUNTRIES
January 18, 2023Business Services
DAVOS, Switzerland, January 17, 2023 – Pfizer Inc.
UCL to begin new trial to assess cough medicine’s impact on Parkinson’s disease
January 17, 2023Medical Communications
Researchers led by a team at University College London (UCL) have began researching the impacts of ambroxol, a common ingredient …
Johnson & Johnson scale back COVID-19 vaccination production
January 17, 2023Manufacturing and Production
US-based Johnson & Johnson (J&J) have begun scaling back production of their COVID-19 vaccine due to demand falling over the …
Thermo Fisher to become founding sponsor of Momentum Labs
January 17, 2023Medical Communications
Thermo Fisher Scientific has announced that it has become a founding sponsor of Momentum Labs in Alachua, Florida, US. The …
Indonesia begins hearing class-action lawsuit after children’s deaths from cough syrup
January 17, 2023Medical Communications
An Indonesian court has begun proceedings to hear a class-action lawsuit against health and finance ministries, the drugs regulator and …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
